Chronic kidney disease trials in Japan

In Japan 13 Also abroad 798

13 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions
Where
Many Locations
Age
18 years and over
People
50,000 worldwide
Run by
Bayer
See details and how to joinNCT06278207
Phase 3Taking people
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
Where
Aira, Amagasaki-shi, Beppu-shi, Chigasaki-shi, Fujinomiya-shi, Hakodate-shi, Hamamatsu, Higashihiroshima-shi, Iizuka-shi, Inashiki-gun, Iwata-shi, Kagoshima, Kamakura-shi, Kanazawa, Kashiwara-shi, Kasugai-shi, Kita-ku, Kitakyushu, Kitakyushu-shi, Kobe, Kumagaya-shi, Kurashiki-shi, Kuse-gun, Kuwana-shi, Kyoto, Matsusaka-shi, Matsuyama, Meguro-ku, Minatoku, Minokamo Shi, Miyakonojo-shi, Morioka, Nagaoka-shi, Naka, Narita-shi, Obihiro-shi, Ōita, Ōme, Ōmihachiman, Osaka, Saga, Sapporo, Sendai, Shibuya-ku, tabashi City, Tanabe-shi, Toyoake-shi, Toyohashi, Tsu, Yaizu-shi, Yokohama, Yoshida-gun
Age
18 years and over
People
5,000 worldwide
Run by
AstraZeneca
See details and how to joinNCT06742723 · EU 2023-506460-14-00
Phase 3Taking people
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Where
Chūōku, Hamadayama, Suginami-ku, Izumisano, Kobe, Kofu, Kumamoto, Shinjuku-ku, Takarazuka, Uji, Wakayama
Age
50 years and over
People
7,140 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07241390 · EU 2025-523123-22-00
No phaseEnrolling by invitation
Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0
Where
Kanagawa, Okinawa
Age
0 Minutes to 2 weeks
People
8,000 worldwide
Run by
Indiana University
See details and how to joinNCT06823115
Phase 2Taking people
Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP
Where
Kamakura, Kasugai, Matsubara, Matsudo
Age
18 years to 80 years
People
180 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07830719 · EU 2026-525974-21-00
Phase 3Taking people
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Where
Chiba, Kasugai, Kawasaki, Kyoto, Matsumoto, Niigata, Okayama, Ōmihachiman, Osaka, Sapporo, Sendai, Toyoake, Toyota, Yokohama
Age
18 years to 100 years
People
540 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04557462 · EU 2023-508690-92-00
Phase 3Taking people
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
Where
Ageo, Asahi-shi, Chiba, Fukaya, Fukui-shi, Izumisano, Izunokuni-shi, Kariya, Kisarazu-shi, Kita-ku, Kitakyusyu-shi, Kofu, Koga-shi, Komatsu-shi, Koshigaya-shi, Kumagaya-shi, Kumamoto, Kurashiki-shi, Kuwana-shi, Kyoto, Matsumoto-shi, Minamiuonuma, Minatoku, Minokamo Shi, Morioka, Nagoya, Naka, Nerima-ku, Osaka, Sendai, Takatsuki-shi, Toride-shi, Tsu, Urayasu, Yokohama
Age
18 years to 99 years
People
2,800 worldwide
Run by
AstraZeneca
See details and how to joinNCT07624305 · EU 2026-526114-90-00
Phase 2/3Taking people
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
Where
Hashima-gun, Higashiosaka-shi, Hiroshima, Hokkaido, Ibaraki, Ichinomiya-shi, Inashiki-gun, Kagoshima, Kamakura-shi, Kanazawa, Kitakyushu-shi, Kurume, Kurume-shi, Kusatsu-shi, Kyoto, Maebashi, Matsubara-shi, Nagaoka-Shi, Nagoya, Ogaki-Shi, Ōmihachiman, Oyama-shi, Sakaimachi, Sapporo, Shinjuku-Ku, Takasaki-Shi, Tsukuba, Ube-shi, Urayasu-shi, Yamagata, Yokohama, Yonago-shi
Age
18 years and over
People
3,110 worldwide
Run by
CSL Behring
See details and how to joinNCT05485961 · EU 2022-500273-14-00
Phase 3Taking people
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
Where
Aira, Akita, Asahikawa-shi, Chūōku, Fujisawa-shi, Fukuoka, Hachioji-shi, Hamamatsu, Hiroshima, Ichikawa-shi, Ina-shi, Iruma-Gun, Izunokuni-shi, Kamakura-shi, Kamiina-gun, Kanazawa, Kasugai-shi, Kasuga-shi, Kawachinagano-shi, Kitakyushu, Kitakyushu-shi, Kumamoto, Kurume, Kuwana-shi, Matsumoto-shi, Minatoku, Minokamo Shi, Moriyama-shi, Nagoya, Naka, Ōita, Okayama, Osaka, Oyama-shi, Sakaishi, Sakushu, Sapporo, Sasebo-shi, Shinjuku-ku, Suita-shi, Suwa-shi, Takasago-shi, Tsu, Ueda-shi, Ushiku-shi, Utsunomiya, Yokohama
Age
18 years and over
People
7,000 worldwide
Run by
AstraZeneca
See details and how to joinNCT07753993 · EU 2025-523994-41-00
Phase 3Taking people
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
Where
Chigasaki-shi, Chikushino-shi, Gifu, Kagoshima, Kitakyushu, Kumamoto, Kyoto, Maebashi, Nagoya, Osaka, Sapporo, Suita-shi, Tachikawa-shi, Toyota-Shi
Age
18 years and over
People
900 worldwide
Run by
AstraZeneca
See details and how to joinNCT07662135 · EU 2025-523940-12-00
Phase 1Taking people
A Study of ONO-3310 in Healthy Adult Male Subjects and Chronic Kidney Disease Patients With Type 2 Diabetes Mellitus
Where
Fukuoka
Age
18 years to 64 years
People
120
Run by
Ono Pharmaceutical Co., Ltd.
See details and how to joinNCT07619157
Phase 2Taking people
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
Where
Aichi, Ibaraki, Kanagawa, Kita-ku, Tokyo, Koriyama-shi, Fukushima, Saitama, Sendai-shi, Miyagi, Siga, Tokyo
Age
18 years and over
People
465 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT06717698 · EU 2024-510846-15-00
No phaseTaking people
Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2
Where
Sakai
Age
20 years and over
People
2,000
Run by
Osaka Metropolitan University
See details and how to joinNCT06694012